Headquartered in North Chicago, IL Fiscal year ends December NYSE: ABBV abbvie.com
AbbVie is a biopharmaceutical company that discovers, develops and commercializes medicines across immunology, neuroscience and oncology. It also sells aesthetics products and services through its Allergan Aesthetics portfolio.
Immunology is its largest franchise, led by the IL-23 inhibitor Skyrizi and the JAK inhibitor Rinvoq, alongside the declining legacy biologic Humira.
Neuroscience products include:
- Vraylar, co-developed with Gedeon Richter.
- Botox Therapeutic.
- The migraine drugs Ubrelvy and Qulipta.
- Vyalev for Parkinson's disease.
- The newly FDA-approved Parkinson's therapy Juvmo (tavapadon).
Oncology includes Venclexta, Imbruvica, Elahere and Epkinly, the last co-developed with Genmab. Aesthetics brands include Botox Cosmetic and Juvederm. Other key products include Mavyret, Creon and Linzess.
The U.S. accounts for the large majority of revenue. AbbVie is expanding its pipeline through acquisitions, most recently Apogee Therapeutics for IL-13 and TSLP-targeting immunology assets. Late-stage candidates include:
- Lutikizumab in hidradenitis suppurativa.
- Etentamig in multiple myeloma.
- Temab-A, an ADC for colorectal and lung cancer.
- ABBV-295, an amylin analog for obesity.
AbbVie is a member of the S&P Dividend Aristocrats Index. Updated
Johnson & Johnson closed at $282.11, clearing its September 3 peak by 1.32%. Gilead and AbbVie also finished higher.
Moves: Nov 9, 2026 · Alpha Vantage daily close
4 more related stocks · 1 has no US listing
The Humira cliff is officially behind them: Skyrizi grew 22.7% and Rinvoq 23.9%, more than covering a 31.2% drop in Humira sales. Management raised full-year adjusted EPS guidance to $13.95 to $13.99 and lifted the quarterly dividend 5.2% to $1.82. The EPS and revenue beats themselves were slim.
A physician-scientist joining the board of a $504.7 billion drugmaker signals where AbbVie wants its oversight depth as Skyrizi and Rinvoq face fresh immunology competition. His Form 3 opens a filing trail worth tracking for future buys.
AbbVie set a new 52-week high at $289.08, topping its October 16 peak by 1.28% and marking the fourth record in a month. The $511 billion drugmaker has climbed out of an April trough near $199.
A 5.5% raise to $1.73 a quarter says management sees cash flow holding up even as Humira fades. Buy after Thursday and you miss this payout; the indicated yield sits at 2.44%.
A 3.1% intraday jump to $284.58 is an outsized day for a $503 billion defensive pharma name, landing a day after new Phase 3 AFFIRM data on subcutaneous SKYRIZI in Crohn's disease. Immunology is the growth engine investors are repricing.
A 3.1% slide to $273.85 lands minutes after new Phase 3 AFFIRM data for subcutaneous Skyrizi in Crohn's disease hit the wire. Skyrizi is the growth engine meant to carry the post-Humira era, so the market's read on this data matters.
AbbVie set a fresh 52-week high at $272.42, the second straight day of records for the drugmaker. Keep an eye on whether it holds.
AbbVie cleared its August record with a fresh 52-week high at $266.28, 0.12% above the prior peak, on the same day it announced FDA approval of JUVMO. A $470.9 billion pharma making new highs is a momentum signal income investors rarely get.
Sessions dumped a big pharma name and Alphabet on the same day, then filed within four days, an unusually fast turnaround that pins down the timing. Paired healthcare and megacap tech selling from a sitting House member is a signal to catch before the next leg of either trade.
Quitting at 58 sounds simple when your savings sit in a Roth. But one hidden clock, and the wrong conversion pulled at the wrong time, can turn tax-free money into a penalty…
A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know…
Six household-name dividend payers hand you a steady paycheck, but one of them gets taxed far harder than the other five. Find out which holding belongs in a Roth first, and how…
A fat yield means nothing if the check bounces. Five payers across telecom, tobacco, pharma, real estate and pipelines show how to test coverage, and one of them carries a debt pile…
Four dividend stocks just delivered strong earnings, but free cash flow and balance sheet strength separate the ones built to keep raising payouts from the ones that just look good on paper.
AbbVie just logged a 33% gain for the year and raised its guidance again, but the real question is whether Skyrizi and a newly closed pipeline deal can push shares even further…
When you’re drawing income from a portfolio, the check size matters less than whether it keeps coming every year. A blue-chip payout is funded by free cash flow left over after the…
Arthritis flares, cholesterol checks and cancer treatments arrive on their own schedule, in recessions and booms alike, which is why healthcare draws attention from retirees building an income plan. It also gives…
Dividends keep paying whether you sell or not, and four healthcare giants quietly generate serious retirement income while you sleep. But not every yield here is as safe as it looks.
AbbVie just handed shareholders their latest raise while your CD rate sits frozen, but the comparison between a guaranteed payment and a growing dividend gets complicated fast once taxes, price swings, and…
Big Tech is pulling Wall Street toward a lower open on Friday, while a lot of earnings reports from energy, healthcare and utility companies keeps blue chips steady. Before the open, a…
HDV switched to monthly payments and split its shares this year, and both moves look dramatic on paper until you dig into what actually changed for retirees counting on that income.
AbbVie built its empire on a single blockbuster drug, then watched biosimilars gut it almost overnight. Whether the replacement pipeline saved investors or left them holding the bag depends on when they…
Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook. However, Merck’s steady, Keytruda-anchored growth tells a very different…
Wall Street spent years dismissing UPS as a broken dividend story, but a fresh earnings beat changed the conversation. These four NYSE stocks now combine rising cash flow with long payout histories,…
AbbVie is a biopharmaceutical company that discovers, develops and commercializes medicines across immunology, neuroscience and oncology. It also sells aesthetics products and services through its Allergan Aesthetics portfolio.
24/7 Wall St.'s 12-month price target for ABBV is $322.26, rated Buy. The Wall Street consensus target is $306.42. ABBV price prediction →
